Bachem Holding AG Company Analysis & Research
Bachem specializes in the development and manufacture of peptides and oligonucleotides, providing products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies. The company operates a critical CDMO (contract development and manufacturing organization) role in the biotech supply chain, serving a growing market demand for peptide-based therapeutics.
Bachem is building new capacity to manufacture peptides at ton-scale for medicines in urgent demand. The company aims for annual sales of more than CHF 1 billion and an EBITDA margin of over 30% in 2026. With strong organic growth and aggressive capacity expansion, Bachem is positioned as the leading peptide CDMO in a high-growth market segment.
Company Overview
Founded: 1971. Headquarters: Bubendorf, Switzerland. Revenue: $781M. Employees: 2,200. Market Cap: $4.58B. Ticker: BANB (SIX Swiss Exchange).
Industry
Pharmaceutical Contract Development and Manufacturing (CDMO) - Peptides & Oligonucleotides
Cyborg Score: 8/10 — Strong
Leading peptide CDMO with structural market tailwinds, aggressive capacity expansion, and consistent execution targeting >CHF 1B revenue by 2026.
Bachem increased sales in Swiss francs by 4.8% to CHF 605.3 million in 2024, with sales increasing by 5.6% in local currencies. Operating EBITDA increased by 5.7% to CHF 176.3 million with an EBITDA margin of 29.1%. Strong execution on capacity expansion and robust order pipeline support growth trajectory.
Key Strategic Insights for Bachem Holding AG
- Commercial API sales reached CHF 327.0 million with a strong increase in patent-protected peptide sales.
- For 2025, Bachem expects growth between 10-15% in local currencies with EBITDA margins in the high twenties.
- CHF 292.2 million invested in 2024 with plans for over CHF 400 million CAPEX in 2025, reflecting major capacity buildout.
- The company has over 2,200 employees navigating its largest expansion process in company history.
Recent Developments
- (July 2025) Full-year 2024 results: CHF 605.3M revenue (+4.8%), EBITDA CHF 176.3M (+5.7%), targeting CHF 1B+ sales by 2026
- (2024) Major CAPEX investment of CHF 292.2M with continued capacity expansion at all sites
- (2025 Guidance) Revenue growth 10-15% expected with EBITDA margins in high twenties and CAPEX >CHF 400M planned
Competitors & Competitive Landscape
- Lonza Group — Integrated CDMO with peptide and oligonucleotide capabilities
- Ferring Pharmaceuticals — Peptide development and manufacturing services
- Dipexium Pharmaceuticals — Specialty pharmaceutical CDMO
Lonza Group is identified as one of Bachem's main competitors. Bachem competes in the specialized CDMO market focused on peptides and oligonucleotides. The market is consolidating around specialized providers, where Bachem holds a leading position due to its peptide manufacturing scale and capabilities.
More Company Research
SCYNEXIS, Inc. Scilex Holding Company Bliss GVS Pharma Limited Hyliion Holdings Corp Magnera Corporation WashTec AG Dan Hotels Ltd Realia Business S.A. First Financial Bancorp Westgold Resources Limited Lion Finance Group PLC Meridian Energy Limited Press Metal Aluminium Holdings Berhad Power Corporation of Canada The Charles Schwab CorporationFull Company Research Reports
Looking for a more in-depth analysis of Bachem Holding AG? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.